BI
BIEI.US Premier Biomedical Inc
- Market cap
- USD 1.15M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BIEI.US undervalued?
Graham numberThe Graham number of Premier Biomedical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Premier Biomedical Inc fundamental analysis
No fundamental analysis for Premier Biomedical Inc yet.
Premier Biomedical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Premier Biomedical Inc
Premier Graphene, Inc. engaged in a hemp-based initiative, developing graphene enhanced formulations for a myriad of commercial and military applications. The company also focused on complementing new EV battery technology as well as state-of-the-art new generation ballistic gear. It serves the defense, aerospace, quantum computing, energy storage, construction, and automotive sectors. It operates in the United States and Mexico. Premier Graphene, Inc. was formerly known as …
Full company profilePremier Biomedical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Premier Biomedical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 39.8K | 39.8K | 14.3K | 1.02K | - | - | - | - | - | - |
| Gross Profit | -2.08K | 14.3K | -73.9K | 1.42K | -1.26K | -1.47K | -1.47K | - | - | - | - |
| Operating Income | -638K | -1.29M | -693K | -327K | -101K | -6.47K | -18.3K | -171K | -57.4K | -87.4K | 11.2K |
| EBITDA | -636K | -3.41M | -6.80K | 20.9K | -98.9K | -5.00K | -16.8K | -3.11K | -57.4K | -87.4K | 11.2K |
| Net Income | -1.77M | -3.76M | -399K | -374K | -403K | -38.8K | -49.3K | -202K | -98.8K | -87.4K | 11.2K |
| EPS | -729 | -1.92 | -0.11 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 39.0K | 209K | 165K | 101K | 4.60K | 3.13K | 3.13K | 7.35K | 3.23K | 3.19K | 47.5K |
| Total Liabilities | 700K | 2.82M | 2.31M | 1.93M | 2.22M | 2.25M | 2.28M | 2.49M | 2.58M | 2.61M | 2.61M |
| Shareholders' Equity | -661K | -2.61M | -2.15M | -1.83M | -2.22M | -2.25M | -2.28M | -2.48M | -2.58M | -2.61M | -2.57M |
| Cash & Short-term Investments | 22.4K | 83.7K | 86.8K | 71.2K | - | - | - | 4.22K | 93.00 | 58.00 | 791.00 |
| Total Debt | 183K | 170K | 310K | 161K | 418K | 436K | 437K | 568K | 608K | 751K | 741K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -484K | -507K | -445K | -344K | -71.2K | -5.00K | 2.93K | -171K | - | - | -78.0K |
| Capital Expenditure | 3.54K | 2.70K | 2.03K | 4.85K | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 |
| Free Cash Flow | -487K | -510K | -447K | -349K | -71.2K | -5.00K | 2.93K | -171K | - | - | -78.0K |
| Ratios | |||||||||||
| ROA | -4,537.2% | -1,800.3% | -241.8% | -370.5% | -8,762.6% | -1,237.1% | -1,571.8% | -2,748.7% | -3,062.9% | -2,739.5% | 23.5% |
| Net Profit Margin | - | -9,466.6% | -1,002.6% | -2,618.9% | -39,603.8% | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Premier Biomedical Inc dividends
Premier Biomedical Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:250 on Jun 27, 2018.
Who owns Premier Biomedical Inc
- Insiders 2.37%
- Institutions 0.00%
- Public & others 97.63%
- Shares outstanding 1.65B
- Free float 976M
Premier Biomedical Inc company profile
- Company name
- Premier Biomedical Inc
- Ticker
- BIEI.US
- Exchange
- USA Stocks
- Sector
- Basic Materials
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 1150 S., El Centro, CA, United States, 92243
- Phone
- 442 270 2302
- Website
- premiergrapheneinc.com
About Premier Biomedical Inc
Premier Graphene, Inc. engaged in a hemp-based initiative, developing graphene enhanced formulations for a myriad of commercial and military applications. The company also focused on complementing new EV battery technology as well as state-of-the-art new generation ballistic gear. It serves the defense, aerospace, quantum computing, energy storage, construction, and automotive sectors. It operates in the United States and Mexico. Premier Graphene, Inc. was formerly known as Nova Graphene Ballistics, Inc. and changed its name to Premier Graphene, Inc. in February 2023. The company was incorporated in 2010 and is headquartered in El Centro, California.
Premier Biomedical Inc management
3- Mr. David CaplanPresident, Chairman of the Board of Directors, Secretary & Treasurer
- Mr. Gustavo CarreñoChief Technology Officer
- Mr. Carl EllerMarketing & Planning Vice-President